Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 19, 2013; 81 (21 supplement 1) Response evaluation in neurofibromatosis and schwannomatosis (REiNS)

Achieving consensus for clinical trials

The REiNS International Collaboration

Scott R. Plotkin, Jaishri O. Blakeley, Eva Dombi, Michael J. Fisher, C. Oliver Hanemann, Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann
First published November 18, 2013, DOI: https://doi.org/10.1212/01.wnl.0000435743.49414.b6
Scott R. Plotkin
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaishri O. Blakeley
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Dombi
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Fisher
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Oliver Hanemann
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin S. Walsh
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela L. Wolters
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte C. Widemann
From the Neurology Department and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston, MA; Department of Neurology, Neurosurgery, and Oncology (J.O.B.), Johns Hopkins, Baltimore, MD; Pediatric Oncology Branch (E.D., P.L.W., B.C.W.), National Cancer Institute, Bethesda, MD; Division of Oncology, Department of Pediatrics (M.J.F.), The Children's Hospital of Pennsylvania, Philadelphia; Plymouth University Peninsula Schools of Medicine and Dentistry (C.O.H.), Plymouth, United Kingdom; and The Jennifer and Daniel Gilbert Neurofibromatosis Institute (K.S.W.), Children's National Medical Center, Washington, DC.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Achieving consensus for clinical trials
The REiNS International Collaboration
Scott R. Plotkin, Jaishri O. Blakeley, Eva Dombi, Michael J. Fisher, C. Oliver Hanemann, Karin S. Walsh, Pamela L. Wolters, Brigitte C. Widemann
Neurology Nov 2013, 81 (21 supplement 1) S1-S5; DOI: 10.1212/01.wnl.0000435743.49414.b6

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
785

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

The neurofibromatoses (NF)—including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis—are related tumor-suppressor syndromes characterized by a predisposition to multiple tumor types and other disease manifestations, which often result in functional disability, reduced quality of life, pain, and, in some cases, malignancy. With increasing knowledge of the biology and pathogenesis of NF, clinical trials with targeted agents directed at NF tumors have become available. Most clinical trials for patients with NF have used designs and endpoints similar to oncology trials. However, differences in the disease manifestations and natural history of NF (compared to cancers) require the development of new designs and endpoints to perform meaningful NF clinical trials. The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established in 2011 at the Children's Tumor Foundation meeting to achieve consensus within the NF community about the design of future clinical trials, with a specific emphasis on endpoints. The REiNS Collaboration includes 7 working groups that focus on imaging of tumor response; functional, visual, patient-reported, and neurocognitive outcomes; whole-body MRI; and disease biomarkers. This supplement includes the first series of recommendations by the REiNS Collaboration. The hope is that these recommendations will be used by members of the group and by researchers outside of the REiNS International Collaboration to standardize the measurement of outcomes and thus improve clinical trials for patients with NF. Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate the approval of drugs for patients with NF.

Glossary

FDA=
US Food and Drug Administration;
NF=
neurofibromatosis;
REiNS=
Response Evaluation in Neurofibromatosis and Schwannomatosis

The neurofibromatoses (NF)—including neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis—are a group of related tumor-suppressor syndromes characterized by a predisposition to multiple nerve sheath tumors. Neurofibromas are the hallmark tumor of NF1, whereas schwannomas are the hallmark of NF2 and schwannomatosis. Patients with NF are at risk for a range of other tumors, including optic gliomas, non-optic gliomas, juvenile myelomonocytic leukemia, malignant peripheral nerve sheath tumors, pheochromocytomas, and gastrointestinal stromal tumors (NF1); ependymomas (NF2); and meningiomas (NF2 and schwannomatosis).1,2 In addition, patients with NF1, NF2, and schwannomatosis are at risk for nontumor manifestations affecting multiple organ systems. Learning disability, cognitive dysfunction, and bony abnormalities are more common in NF1 patients, cataracts and neuropathy in NF2 patients, and chronic pain in schwannomatosis patients.3 Together, these disease manifestations may result in functional disability and reduced quality of life for patients.

Standard treatment for most histologically benign NF tumors is limited to surgery. Over the past 2 decades, researchers have used cell cultures and mouse models to better understand the biology, pathogenesis, and array of disease manifestations in NF1, NF2, and schwannomatosis. The increased availability of targeted antitumor agents in the early 2000s led directly to the design and execution of clinical trials for plexiform neurofibroma in NF1 patients.4,–,6 In 2007, the Department of Defense Neurofibromatosis Research Program established the Neurofibromatosis Clinical Trials Consortium with a mandate to accelerate the development of multicenter clinical trials for affected patients. Under the leadership of Drs. Roger Packer and Bruce Korf, the Consortium was refunded in 2012 and has established a goal of hosting 6 clinical trials in the next 5 years.

Most early NF trials adopted trial designs similar to those used in oncology trials. However, due to differences in the manifestations of NF and its natural history compared to solid cancers, standard trial designs and endpoints used in oncology have limited applicability to NF trials for histologically benign tumors. The NF community continues to struggle with the optimum design of clinical trials for this group of patients. Currently, there is a wide range of endpoints used for clinical trials in NF patients, with no published consensus among investigators. The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established in 2011 at the Children's Tumor Foundation meeting to achieve consensus within the NF community about future clinical trials and to accelerate the identification of agents that will benefit individuals with NF. This supplement summarizes the recommendations from the REiNS group to date.

ORGANIZATION OF THE REiNS INTERNATIONAL COLLABORATION

The REiNS Collaboration is organized around 7 working groups that focus on the following topics: imaging of tumor response, functional outcomes, visual outcomes, patient-reported outcomes, neurocognitive outcomes, whole-body MRI, and disease biomarkers. Leaders of the 7 working groups were identified based on their expertise at the initial meeting in 2011. The 7 group leaders comprise the leadership team of the overall REiNS Collaboration. Membership in each working group is open to any interested party, and representatives from patient advocacy groups and funding agencies have been invited to participate in the effort. Each REiNS group establishes a meeting schedule; the majority of meetings are held by teleconference. In-person meetings of the entire group are held at least twice per year to coordinate efforts among the working groups and to achieve consensus for recommendations. The leadership team held a preliminary meeting with the US Food and Drug Administration (FDA) to discuss endpoints for NF trials. At this meeting, the FDA encouraged the REiNS Collaboration to use validated functional and patient-reported outcomes for trials intended for drug approval.

SUMMARY OF PUBLISHED CLINICAL TRIALS FOR NEUROFIBROMATOSIS

Clinical trials for NF patients published to date are shown in the table. In these 15 studies, there has been a range of designs and primary and secondary endpoints. The majority of phase II studies were designed with imaging response as the primary endpoint. In these studies, change in 1- or 2-dimensional measurements or volume was used as the primary outcome measure and a variety of secondary endpoints was reported. Of note, few of these studies included endpoints evaluating functional outcomes (e.g., hearing or vision), patient-reported outcomes (e.g., pain), or neurocognitive outcomes. Thus, the majority of these trials used endpoints adapted from oncology trials to establish drug activity against NF-related tumors.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Published clinical trials for neurofibromatosis patients in the literature

WHY CURRENT ENDPOINTS ARE NOT APPROPRIATE FOR NF TRIALS

A diagnosis of NF1 or NF2 is associated with decreased survival compared with nonaffected controls.7 However, overall survival for patients with histologically benign tumors is extended, and use of overall survival as an endpoint for clinical trials in NF is not appropriate. Many NF tumors are complex and grow substantially more slowly than solid cancers, which limits the utility of standard response criteria used in solid tumor trials.8,9 In addition, there has been increasing concern by the NIH and the FDA about the use of imaging response (a decrease in tumor size) as a surrogate marker for clinical improvement. This concern stems from the finding that decreases in tumor size may not lead to clinical improvement for patients. For this reason, there has been increased support for the use of clinical and functional outcomes and extensive discussion about the most appropriate endpoints for NF patients since this group is burdened with significant morbidity.

FUTURE GOALS/PLANS

This supplement presents the initial progress of several of the working groups and includes the first series of consensus recommendations for NF clinical trial endpoints by the REiNS International Collaboration. The goal of the group's efforts is to recommend outcome measures and methodologies that will be used by REiNS members and by other researchers to standardize endpoints for NF clinical trials. Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate the approval of drugs for patients with NF. We expect that these recommendations will be modified with time as more data on NF-specific endpoints become available. Until that time, these guidelines may help researchers design clinical trials for patients with NF and improve the comparability of results between trials.

AUTHOR CONTRIBUTIONS

SR Plotkin: drafting the manuscript, study concept, interpretation of data. JO Blakeley: revising the manuscript for content, study concept, interpretation of data. E Dombi: revising the manuscript for content, study concept, interpretation of data. MJ Fisher: revising the manuscript for content, study concept, interpretation of data. CO Hanemann: revising the manuscript for content, study concept, interpretation of data. KS Walsh: revising the manuscript for content, study concept, interpretation of data. PL Wolters: revising the manuscript for content, study concept, interpretation of data. BC Widemann: drafting the manuscript, study concept, interpretation of data.

STUDY FUNDING

Supported by the Children's Tumor Foundation.

DISCLOSURE

S. Plotkin has been reimbursed by the American Academy of Neurology and the Children's Tumor Foundation for travel for educational activities. He has received research support from the Department of Defense (W81XWH-091-0182, NF050202, W81XWH-12-1-0155, PI), the Children's Tumor Foundation (PI), and Johns Hopkins Medical Institutes (site PI). J. Blakely received travel support from the Children's Tumor Foundation, the American Academy of Neurology, and the American Society of Clinical Oncology. She receives research support from GlaxoSmithKline, Sanofi-Aventis, Eli Lilly, the Cancer Therapy Evaluation Program, and the Children's Tumor Foundation. E. Dombi reports no disclosures. M. Fisher received reimbursement from the Children's Tumor Foundation to attend their annual Neurofibromatosis Conference, is funded by the Department of Defense (W81XWH-12-1-0155, W81XWH-05-1-0615), Thrasher Research Fund, the Children's Tumor Foundation, and Sarcoma Alliance for Research through Collaboration, and received research support from the Pediatric Low Grade Astrocytoma Foundation, Bayer, Children's Discovery Institute, NIH (NR009651-01), and the Department of Defense (W81XWH-08-1-0051). C. Hanemann received a travel grant from Baxter International and receives grant support from Novartis, The Brain Tumor Charity, CR-UK, and Action Medical Research. K. Walsh reports no disclosures. P. Wolters received research support from the Childhood Brain Tumor Foundation and holds stock options in Bristol-Meyers-Squibb, General Electric, and Zimmer Holdings, Inc. B. Widemann is a member of the scientific advisory board of the Neurofibromatosis Therapeutic Acceleration Program. She is a member of the editorial board of The Oncologist and an associate editor of Frontiers in Pediatric Oncology. Go to Neurology.org for full disclosures.

Acknowledgment

The authors would like to acknowledge the support of the Children's Tumor Foundation for the REiNS International Collaboration and for this supplement.

Footnotes

  • REiNS International Collaboration members are listed on the Neurology® Web site at www.neurology.org.

  • Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Supplemental data at www.neurology.org

  • Received May 9, 2013.
  • Accepted in final form August 13, 2013.
  • © 2013 American Academy of Neurology

REFERENCES

  1. 1.↵
    1. Ferner RE
    . Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007;6:340–351.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Evans DG
    . Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Merker VL,
    2. Esparza S,
    3. Smith MJ,
    4. Stemmer-Rachamimov A,
    5. Plotkin SR
    . Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist 2012;17:1317–1322.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gupta A,
    2. Cohen BH,
    3. Ruggieri P,
    4. Packer RJ,
    5. Phillips PC
    . Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology 2003;60:130–132.
    OpenUrl
  5. 5.↵
    1. Kim A,
    2. Dombi E,
    3. Tepas K,
    4. et al
    . Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer 2013;60:396–401.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Babovic-Vuksanovic D,
    2. Ballman K,
    3. Michels V,
    4. et al
    . Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 2006;67:1860–1862.
    OpenUrl
  7. 7.↵
    1. Wilding A,
    2. Ingham SL,
    3. Lalloo F,
    4. et al
    . Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet 2012;49:264–269.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Miller AB,
    2. Hoogstraten B,
    3. Staquet M,
    4. Winkler A
    . Reporting results of cancer treatment. Cancer 1981;47:207–214.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Eisenhauer EA,
    2. Therasse P,
    3. Bogaerts J,
    4. et al
    . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
    OpenUrlCrossRefPubMed
  10. 10.
    1. Riccardi VM
    . A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol 1993;129:577–581.
    OpenUrlCrossRefPubMed
  11. 11.
    1. Packer RJ,
    2. Gutmann DH,
    3. Rubenstein A,
    4. et al
    . Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002;58:1461–1470.
    OpenUrl
  12. 12.
    1. Widemann BC,
    2. Salzer WL,
    3. Arceci RJ,
    4. et al
    . Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006;24:507–516.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    1. Widemann B,
    2. Dombi E,
    3. Gillespie A,
    4. et al
    . Phase II randomized, flexible cross-over, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in pediatric patients with NF1 and progressive plexiform neurofibromas. Presented at Children's Tumor Foundation Conference; June, 2009. Abstract.
  14. 14.
    1. Babovic-Vuksanovic D,
    2. Widemann BC,
    3. Dombi E,
    4. et al
    . Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. Pediatr Neurol 2007;36:293–300.
    OpenUrlCrossRefPubMed
  15. 15.
    1. Krab LC,
    2. de Goede-Bolder A,
    3. Aarsen FK,
    4. et al
    . Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008;300:287–294.
    OpenUrlCrossRefPubMed
  16. 16.
    1. Ater J,
    2. Holmes E,
    3. Zhou T,
    4. et al
    . Results of COG protocol A9952- a randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro-oncol 2008;10:451. Abstract.
    OpenUrl
  17. 17.
    1. Weiss B,
    2. Fisher M,
    3. Dombi E,
    4. et al
    . Phase II study of the mTOR inhibitor sirolimus for non-progressive NF1-associated plexiform neurofibromas: a Neurofibromatosis Consortium Study. Presented at 14th International Symposium on Pediatric Neuro-Oncology Abstract Book 2010; ii43. Abstract.
  18. 18.
    1. Acosta MT,
    2. Kardel PG,
    3. Walsh KS,
    4. Rosenbaum KN,
    5. Gioia GA,
    6. Packer RJ
    . Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol 2011;45:241–245.
    OpenUrlCrossRefPubMed
  19. 19.
    1. Jakacki RI,
    2. Dombi E,
    3. Potter DM,
    4. et al
    . Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas. Neurology 2011;76:265–272.
    OpenUrlCrossRef
  20. 20.
    1. Karajannis MA,
    2. Legault G,
    3. Hagiwara M,
    4. et al
    . Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012;14:1163–1170.
    OpenUrlAbstract/FREE Full Text
  21. 21.
    1. Robertson KA,
    2. Nalepa G,
    3. Yang FC,
    4. et al
    . Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012;13:1218–1224.
    OpenUrlCrossRefPubMed
  22. 22.
    1. Fisher MJ,
    2. Meyer J,
    3. Roberts T,
    4. et al
    . Feasibility of photodynamic therapy using intratumoral light in children with neurofibromatosis type 1 and plexiform neurofibromas. Neuro-oncol 2012;14. i18.Abstract.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • ORGANIZATION OF THE REiNS INTERNATIONAL COLLABORATION
    • SUMMARY OF PUBLISHED CLINICAL TRIALS FOR NEUROFIBROMATOSIS
    • WHY CURRENT ENDPOINTS ARE NOT APPROPRIATE FOR NF TRIALS
    • FUTURE GOALS/PLANS
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Topics Discussed

  • All Pediatric
  • Neurofibromatosis
  • Clinical trials Methodology/study design
  • Nerve tumor

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise